Merck announced the initiation of KANDLELIT-007, a Phase 3 clinical trial evaluating calderasib (MK-1084), an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA QLEX(pembrolizumab and berahyaluronidase alfa-pmph) for the first-line treatment of patients with KRAS G12C-mutant, advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC). This randomized, unblinded open-label, multicenter clinical trial (NCT07190248) will evaluate calderasib given orally once daily in combination with KEYTRU DA QLEX administered subcutaneously, compared with subcutaneous KEYTRUDA QLE X in combination with intravenous pemetrexed and chemotherapy (carboplatin or cisplatin), in newly diagnosed patients with KRAS G12 C-mutant advanced or metastatic nonsqu Famous NSCLC. KEYTRUDA and KEYTRUDA QLEx, as single agents, are each indicated for the first-line treatment the adult patients with NSCLC expressing PD-L1 [tumor proportion score (TPS) 1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.
KEYTRUDA and KeyTRUDA QLEX, as single agents, are Each indicated for the treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS 1) as determined by an FDA- approved test. KEYTRUDA andKEYTRUDA QLEX are each indicated, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment. KEYTRUDA and keyTRUDA QLEX were each indicated, in combination with trastuzumab, fluoropyrimidine- and Platinum-containing chemotherapy, for the First-line treatment of adults with locally advanced unresectable and metastatic HER2-positive Gastric or gastroesophageAL junction (GEJ) adENocarcinoma whose tumors expressed PD-L1 (C PS 1) as determined by anFDA-approved test.
KEYTRUDA & KEYTRUDA and KEY TRUDA QLEX are Each indicated, in combination with fluorOPyrimidine- and platinum- containing chemotherapy, for the first- line treatment of adults with locally advanced unsectable or metastatic HER 2-negative gastric or gastroesophagesal junction (GEJ) Adenocarcinoma whose tumor express PD-L1 (CPS 1) as determined by a FDA-approved test. KEYTR UDA and KEYTRUDAQLEX are each indicated, In combination with fluoropyrimidine - and platinum-containing chemotherapy, For the first-line treatment of adults with local advanced unresectable or metast metastatic HER2-negative gastric or Gastesophageal junction (GEJ) adenocarc inoma whose tumors express PD- L1 (CPS 1) As determined by an FDA-approved tests. KEYTRUDA and keysTRUDA QLEX is each indicated, in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with tumors that expressPD-L1 (CPS1).
